[
  {
    "ts": null,
    "headline": "How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline",
    "summary": "In recent days, Gilead Sciences announced a series of developments, including settlement agreements that extend Biktarvy's U.S. exclusivity to 2036 and updates on innovative therapies in HIV prevention and oncology through collaborations with partners like Nurix Therapeutics. Growing analyst confidence in Gilead has been supported by strengthened intellectual property protections and a pipeline of new drug candidates, signaling optimism for the company’s long-term product diversification...",
    "url": "https://finnhub.io/api/news?id=df02835d4e858bcf2872693b177d9c68c94f5b9b97aa53e37a9947734b1be7b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760198862,
      "headline": "How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline",
      "id": 137063675,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In recent days, Gilead Sciences announced a series of developments, including settlement agreements that extend Biktarvy's U.S. exclusivity to 2036 and updates on innovative therapies in HIV prevention and oncology through collaborations with partners like Nurix Therapeutics. Growing analyst confidence in Gilead has been supported by strengthened intellectual property protections and a pipeline of new drug candidates, signaling optimism for the company’s long-term product diversification...",
      "url": "https://finnhub.io/api/news?id=df02835d4e858bcf2872693b177d9c68c94f5b9b97aa53e37a9947734b1be7b0"
    }
  },
  {
    "ts": null,
    "headline": "How the Story Behind Gilead Is Evolving in Light of Key Analyst and Industry Updates",
    "summary": "Gilead Sciences has seen a slight increase in its consensus analyst price target, rising from $124.91 to $126.31. This subtle uptick reflects an improved outlook for Gilead's core businesses as analysts weigh recent positive developments and ongoing risks. Read on to discover what is driving this shift, and find out how you can stay informed as the company's story continues to evolve. What Wall Street Has Been Saying Recent commentary from Wall Street analysts highlights a balance of optimism...",
    "url": "https://finnhub.io/api/news?id=c46af13ca7f902680892ad9ba0ab066673a06be562cf8842642134b47bacd448",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760195187,
      "headline": "How the Story Behind Gilead Is Evolving in Light of Key Analyst and Industry Updates",
      "id": 137063676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences has seen a slight increase in its consensus analyst price target, rising from $124.91 to $126.31. This subtle uptick reflects an improved outlook for Gilead's core businesses as analysts weigh recent positive developments and ongoing risks. Read on to discover what is driving this shift, and find out how you can stay informed as the company's story continues to evolve. What Wall Street Has Been Saying Recent commentary from Wall Street analysts highlights a balance of optimism...",
      "url": "https://finnhub.io/api/news?id=c46af13ca7f902680892ad9ba0ab066673a06be562cf8842642134b47bacd448"
    }
  },
  {
    "ts": null,
    "headline": "Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones",
    "summary": "NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential, and key risks.",
    "url": "https://finnhub.io/api/news?id=38be8bb0f29d395d11e401edffb9f7accd6e4200a3825c01d33150ffaa4ff0f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760170387,
      "headline": "Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones",
      "id": 137049891,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217864526/image_2217864526.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential, and key risks.",
      "url": "https://finnhub.io/api/news?id=38be8bb0f29d395d11e401edffb9f7accd6e4200a3825c01d33150ffaa4ff0f9"
    }
  },
  {
    "ts": null,
    "headline": "3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR",
    "summary": "With investors on edge as the world's two largest economies go head-to-head again, seeking out stocks that can offer defensive safety in the portfolio may be necessary",
    "url": "https://finnhub.io/api/news?id=a635c1a41bed686b7d30703da43f55507bd15a5f2ba55c23d5518e60d91fc2bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760144880,
      "headline": "3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR",
      "id": 137048955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "With investors on edge as the world's two largest economies go head-to-head again, seeking out stocks that can offer defensive safety in the portfolio may be necessary",
      "url": "https://finnhub.io/api/news?id=a635c1a41bed686b7d30703da43f55507bd15a5f2ba55c23d5518e60d91fc2bb"
    }
  }
]